vs

Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $11.9M, roughly 1.1× ASCENT INDUSTRIES CO.). ASCENT INDUSTRIES CO. runs the higher net margin — -8.8% vs -1398.3%, a 1389.6% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 13.3%). ASCENT INDUSTRIES CO. produced more free cash flow last quarter ($-196.0K vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -34.9%).

Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

ACNT vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.1× larger
RNA
$12.5M
$11.9M
ACNT
Growing faster (revenue YoY)
RNA
RNA
+420.7% gap
RNA
434.0%
13.3%
ACNT
Higher net margin
ACNT
ACNT
1389.6% more per $
ACNT
-8.8%
-1398.3%
RNA
More free cash flow
ACNT
ACNT
$156.7M more FCF
ACNT
$-196.0K
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-34.9%
ACNT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ACNT
ACNT
RNA
RNA
Revenue
$11.9M
$12.5M
Net Profit
$-1.0M
$-174.4M
Gross Margin
14.6%
Operating Margin
-21.0%
-1513.5%
Net Margin
-8.8%
-1398.3%
Revenue YoY
13.3%
434.0%
Net Profit YoY
-1.2%
-117.0%
EPS (diluted)
$-0.11
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACNT
ACNT
RNA
RNA
Q4 25
$11.9M
Q3 25
$19.7M
$12.5M
Q2 25
$18.7M
$3.8M
Q1 25
$24.7M
$1.6M
Q4 24
$10.5M
$3.0M
Q3 24
$20.9M
$2.3M
Q2 24
$21.5M
$2.0M
Q1 24
$28.0M
$3.5M
Net Profit
ACNT
ACNT
RNA
RNA
Q4 25
$-1.0M
Q3 25
$-2.1M
$-174.4M
Q2 25
$6.3M
$-157.3M
Q1 25
$-2.3M
$-115.8M
Q4 24
$-1.0M
$-102.3M
Q3 24
$-6.2M
$-80.4M
Q2 24
$-926.0K
$-70.8M
Q1 24
$-5.5M
$-68.9M
Gross Margin
ACNT
ACNT
RNA
RNA
Q4 25
14.6%
Q3 25
29.7%
Q2 25
26.1%
Q1 25
19.3%
Q4 24
24.3%
Q3 24
14.4%
Q2 24
13.1%
Q1 24
8.3%
Operating Margin
ACNT
ACNT
RNA
RNA
Q4 25
-21.0%
Q3 25
-4.1%
-1513.5%
Q2 25
-14.4%
-4448.7%
Q1 25
-4.2%
-8360.9%
Q4 24
-25.4%
-4069.6%
Q3 24
-9.4%
-4200.9%
Q2 24
-8.6%
-4040.4%
Q1 24
-15.5%
-2178.6%
Net Margin
ACNT
ACNT
RNA
RNA
Q4 25
-8.8%
Q3 25
-10.6%
-1398.3%
Q2 25
33.7%
-4089.3%
Q1 25
-9.3%
-7360.0%
Q4 24
-9.8%
-3439.5%
Q3 24
-29.5%
-3441.7%
Q2 24
-4.3%
-3461.8%
Q1 24
-19.7%
-1943.4%
EPS (diluted)
ACNT
ACNT
RNA
RNA
Q4 25
$-0.11
Q3 25
$-0.22
$-1.27
Q2 25
$0.65
$-1.21
Q1 25
$-0.23
$-0.90
Q4 24
$-0.11
$-0.80
Q3 24
$-0.61
$-0.65
Q2 24
$-0.09
$-0.65
Q1 24
$-0.54
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACNT
ACNT
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$57.6M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$87.0M
$1.9B
Total Assets
$111.9M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACNT
ACNT
RNA
RNA
Q4 25
$57.6M
Q3 25
$58.0M
$350.2M
Q2 25
$60.5M
$243.9M
Q1 25
$14.3M
$254.2M
Q4 24
$16.1M
$219.9M
Q3 24
$8.5M
$370.2M
Q2 24
$3.6M
$575.8M
Q1 24
$1.3M
$471.4M
Total Debt
ACNT
ACNT
RNA
RNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACNT
ACNT
RNA
RNA
Q4 25
$87.0M
Q3 25
$87.1M
$1.9B
Q2 25
$89.7M
$1.2B
Q1 25
$91.2M
$1.3B
Q4 24
$93.5M
$1.4B
Q3 24
$94.7M
$1.5B
Q2 24
$101.0M
$1.2B
Q1 24
$102.0M
$830.9M
Total Assets
ACNT
ACNT
RNA
RNA
Q4 25
$111.9M
Q3 25
$119.9M
$2.1B
Q2 25
$122.6M
$1.4B
Q1 25
$152.5M
$1.5B
Q4 24
$147.3M
$1.6B
Q3 24
$148.6M
$1.6B
Q2 24
$158.2M
$1.3B
Q1 24
$161.0M
$951.5M
Debt / Equity
ACNT
ACNT
RNA
RNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACNT
ACNT
RNA
RNA
Operating Cash FlowLast quarter
$266.0K
$-156.2M
Free Cash FlowOCF − Capex
$-196.0K
$-156.9M
FCF MarginFCF / Revenue
-1.7%
-1257.6%
Capex IntensityCapex / Revenue
3.9%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-2.1M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACNT
ACNT
RNA
RNA
Q4 25
$266.0K
Q3 25
$1.3M
$-156.2M
Q2 25
$-1.4M
$-199.7M
Q1 25
$-700.0K
$-124.8M
Q4 24
$8.8M
$-99.9M
Q3 24
$3.4M
$-65.6M
Q2 24
$2.2M
$-65.0M
Q1 24
$263.0K
$-70.4M
Free Cash Flow
ACNT
ACNT
RNA
RNA
Q4 25
$-196.0K
Q3 25
$695.0K
$-156.9M
Q2 25
$-1.5M
$-203.0M
Q1 25
$-1.0M
$-128.6M
Q4 24
$8.4M
$-103.8M
Q3 24
$3.1M
$-67.3M
Q2 24
$1.9M
$-65.5M
Q1 24
$25.0K
$-71.3M
FCF Margin
ACNT
ACNT
RNA
RNA
Q4 25
-1.7%
Q3 25
3.5%
-1257.6%
Q2 25
-8.3%
-5277.1%
Q1 25
-4.1%
-8174.3%
Q4 24
80.6%
-3491.0%
Q3 24
15.1%
-2881.8%
Q2 24
9.1%
-3204.6%
Q1 24
0.1%
-2012.3%
Capex Intensity
ACNT
ACNT
RNA
RNA
Q4 25
3.9%
Q3 25
3.1%
5.7%
Q2 25
0.8%
86.9%
Q1 25
1.3%
238.6%
Q4 24
3.7%
131.7%
Q3 24
1.3%
72.9%
Q2 24
1.0%
26.0%
Q1 24
0.9%
25.8%
Cash Conversion
ACNT
ACNT
RNA
RNA
Q4 25
Q3 25
Q2 25
-0.22×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACNT
ACNT

Other$6.1M52%
Transferred At Point In Time$5.7M48%

RNA
RNA

Segment breakdown not available.

Related Comparisons